Bladder Cancer

Enfortumab Vedotin Shows Durable Responses in Pivotal Phase 2 Study of Advanced Urothelial Cancer

October 12, 2020

Enfortumab vedotin-ejfv induced durable responses as treatment of patients with locally advanced or metastatic urothelial cancer who have previously received immunotherapy but not a prior platinum-containing chemotherapy and are not eligible for cisplatin.

DFS Improvement Shown With Nivolumab for High-Risk Urothelial Cancer

September 28, 2020

Nivolumab monotherapy administered after surgery demonstrated a significant improvement in disease-free survival compared with placebo in patients with high-risk, muscle-invasive urothelial carcinoma, for all patients randomized in the phase 3 CheckMate-274 trial and those with PD-L1 ≥1% in their tumors, meeting the primary end point of the study.

Sacituzumab Govitecan Sustains Clinical Activity in Patients With Heavily Pretreated mUC

September 20, 2020

Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

Durvalumab With or Without Tremelimumab Fails to Meet OS Endpoints in Urothelial Cancer

September 19, 2020

The co-primary end points of overall survival in patients with metastatic urothelial cancer were not met in the phase 3 DANUBE trial of durvalumab in combination with tremelimumab and durvalumab monotherapy, according to results presented at the 2020 ESMO Virtual Congress.